Aspirin as secondary prevention in colorectal cancer liver metastasis (ASAC trial): study protocol for a multicentre randomized placebo-controlled trial

Background Colorectal cancer is one the most common cancers in the western world with increasing incidence. Approximately 50% of the patients develop liver metastases. Resection of liver metastases is the treatment of choice although almost half of the resected patients get recurrence in the liver....

Full description

Saved in:
Bibliographic Details
Published in:Current controlled trials in cardiovascular medicine 2021-09, Vol.22 (1), p.642-642, Article 642
Main Authors: Yaqub, Sheraz, Bjarnbeth, Bjarn Atle, Angelsen, Jon-Helge, Fristrup, Claus Wilki, Granbech, Jon Erik, Hemmingsson, Oskar, Isaksson, Bengt, Juel, Ingebjarg Soterud, Larsen, Peter Nargaard, Lindell, Gert, Mortensen, Frank Viborg, Mortensen, Kim Erlend, Rizell, Magnus, Sandström, Per, Sandvik, Oddvar Mathias, Sparrelid, Ernesto, Taflin, Helena, Taskén, Kjetil, Brudvik, Kristoffer W, Fretland, Ãsmund A, Horn, Arild, Kleive, Dyre, Labori, Knut J, Lassen, Kristoffer, Rasok, Bård I, Sareide, Jon A, Tholfsen, Tore, Villanger, Olaug, Waage, Anne
Format: Article
Language:English
Subjects:
Acetylsalicylic acid
adenomas
Antigens
antitumor immune-responses
Apoptosis
Aspirin
Cancer and Oncology
Cancer och onkologi
Cancer therapies
Care and treatment
Clinical medicine
Colorectal cancer
cyclooxygenase-2
Diagnosis
Diseases
follow-up
Gastrointestinal surgery
Hospitals
inhibition
Kinases
Kirurgi
Liver
Liver metastases
Lymphocytes
Medical research
Medicine
Metastasis
Mortality
Mutation
Patient outcomes
pik3ca mutation
Prevention
regulatory t-cells
Relapse
Research & Experimental Medicine
Secondary prevention
Study Protocol
suppression
Surgery
Testing
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Colorectal cancer is one the most common cancers in the western world with increasing incidence. Approximately 50% of the patients develop liver metastases. Resection of liver metastases is the treatment of choice although almost half of the resected patients get recurrence in the liver. Methods The ASAC trial is a Scandinavian, multicentre, double-blinded, randomized, placebo-controlled study to determine whether adjuvant treatment with low-dose aspirin (acetylsalicylic acid (ASA)) can improve disease-free survival in patients treated for colorectal cancer liver metastases (CRCLM). Up to 800 patients operated for CRCLM will be randomized to Arm#1 ASA 160 mg once daily or Arm#2 Placebo, for a period of 3 years or until disease recurrence. The patients will be recruited at all major hepatobiliary surgical units in Norway, Sweden and Denmark and have follow-up according to standard of care and the National Guidelines. Discussion The ASAC trial will be the first clinical interventional trial to assess the potential beneficial role of ASA in recurrence of CRCLM and survival. ASA is an inexpensive, well-tolerated and easily accessible drug that will be highly potential as adjuvant drug in secondary prevention of CRCLM if the study shows a beneficial effect. We will also determine the effect of ASA as adjuvant treatment on Health-Related Quality of Life and the cost-effectiveness. Trial registration ClinicalTrials.gov NCT03326791. Registered on 31 October 2017. Keywords: Colorectal cancer, Liver metastases, Aspirin, Acetylsalicylic acid, Secondary prevention
ISSN:1745-6215
1745-6215
DOI:10.1186/s13063-021-05587-w